Indian Experience with adalimumab in rheumatology

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Indian Experience with adalimumab in rheumatology
Adalimumab, a TNF inhibitor, has become an important therapeutic option in Indian rheumatology for treating autoimmune conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Its introduction in India has significantly expanded treatment options for patients who may not respond to conventional DMARDs. The experience with adalimumab in India has been largely positive, with many patients showing improvements in joint pain, mobility, and overall disease activity.
However, cost remains a significant barrier for widespread use, as biologics like adalimumab are expensive. The availability of biosimilars has improved access, helping to reduce the financial burden for patients. Indian rheumatologists have reported good clinical outcomes with adalimumab, but regular monitoring for infections and other side effects is emphasized due to the immunosuppressive nature of the drug. Overall, adalimumab has made a notable impact on managing chronic rheumatologic diseases in India.
Therefore, get an overall knowledge of indian experience with adalimumab in rheumatology
 

See More Webinars @ Hidoc Webinars